Analysts expect that Neuronetics, Inc. (NASDAQ:STIM – Get Rating) will post earnings per share of ($0.41) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Neuronetics’ earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.42). Neuronetics reported earnings of ($0.31) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 32.3%. The firm is scheduled to issue its next earnings results before the market opens on Monday, January 1st.
According to Zacks, analysts expect that Neuronetics will report full year earnings of ($1.69) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.63). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.62) to ($0.85). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Neuronetics.
Neuronetics (NASDAQ:STIM – Get Rating) last announced its earnings results on Tuesday, March 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. Neuronetics had a negative return on equity of 33.24% and a negative net margin of 56.39%. During the same period in the previous year, the firm posted ($0.19) earnings per share.
In other Neuronetics news, major shareholder Cannell Capital Llc bought 22,062 shares of the company’s stock in a transaction on Friday, March 25th. The shares were bought at an average price of $2.99 per share, for a total transaction of $65,965.38. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Stephen Furlong sold 10,029 shares of the firm’s stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $3.00, for a total value of $30,087.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 147,435 shares of company stock valued at $434,119 and have sold 19,929 shares valued at $61,635. 5.20% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. TownSquare Capital LLC lifted its position in shares of Neuronetics by 39.0% during the 1st quarter. TownSquare Capital LLC now owns 35,718 shares of the company’s stock valued at $108,000 after acquiring an additional 10,020 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Neuronetics during the first quarter worth $57,000. Norges Bank acquired a new stake in Neuronetics in the fourth quarter valued at $1,174,000. Barclays PLC increased its position in shares of Neuronetics by 197.0% in the fourth quarter. Barclays PLC now owns 30,972 shares of the company’s stock valued at $138,000 after buying an additional 20,543 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Neuronetics by 1.4% in the 4th quarter. BlackRock Inc. now owns 1,594,473 shares of the company’s stock worth $7,112,000 after buying an additional 22,773 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.
STIM stock opened at $2.44 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.34 and a quick ratio of 6.93. The firm has a market capitalization of $64.97 million, a P/E ratio of -2.03 and a beta of 2.35. The company has a 50 day moving average price of $3.05. Neuronetics has a twelve month low of $2.42 and a twelve month high of $17.92.
About Neuronetics (Get Rating)
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
- Get a free copy of the StockNews.com research report on Neuronetics (STIM)
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Knight-Swift Transportation Stock is a Logistics Winner
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.